CoChat

Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects

Open access
Dolder, Patrick C., Strajhar, Petra, Vizeli, Patrick, Hammann, Felix, Odermatt, Alex, Liechti, Matthias E. · 2017 · Frontiers in Pharmacology
Cited by 57

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Rationale Lisdexamfetamine is a prodrug of D-amphetamine used for the treatment of attention-deficit/hyperactivity disorder (ADHD). Lisdexamfetamine is thought to have a prolonged pharmacokinetic profile compared with oral D-amphetamine, possibly associated with lower drug liking and a lower risk of oral misuse. However, differences in the pharmacokinetics and pharmacodynamics of lisdexamfetamine and D-amphetamine have not been directly compared. Methods Equimolar doses of D-amphetamine (40mg) and lisdexamfetamine (100mg), and placebo were administered in 24 healthy subjects in a randomized, double-blind, placebo-controlled, cross-over study. Plasma concentrations of amphetamine, subjective effects, and vital signs were repeatedly assessed. The pharmacokinetic parameters were determined using compartmental modeling. Results The increase in plasma concentrations of amphetamine had a 0.6±0.6 h (mean±SD) longer lag time and reached peak levels 1.1±1.5 h later after lisdexamfetamine administration compared with D-amphetamine administration, but no differences in maximal concentrations or total exposure (AUC) were found between the two treatments. Consistent with the pharmacokinetics, the subjective and cardiovascular stimulant effects of lisdexamfetamine also occurred later compared with D-amphetamine. However, no differences in peak ratings of potentially abuse-related subjective drug effects (e.g., drug liking, drug high, stimulation, happy, well-being, and self-confidence) were observed after lisdexamfetamine administration compared with D-amphetamine administration. Lisdexamfetamine and D-amphetamine also produced similar peak increases in mean arterial blood pressure, heart rate, body temperature, pupil size, and adverse effects. Conclusions The pharmacokinetics and pharmacodynamics of lisdexamfetamine are similar to D-amphetamine administered 1h later. Lisdexamfetamine is likely associated with a similar risk of oral abuse as D-amphetamine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2017.00617

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. Adler, Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder., Behav. Brain Funct., 5, 10.1186/1744-9081-5-34 · DOI · Paper page
  2. Angrist, 1987, Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects., Biol. Psychiatry, 22, 1357, 10.1016/0006-3223(87)90070-9 · DOI · Paper page
  3. Banks, 2015, Preclinical assessment of lisdexamfetamine as an agonist medication candidate for cocaine addiction: effects in rhesus monkeys trained to discriminate cocaine or to self-administer cocaine in a cocaine versus food choice procedure., Int. J. Neuropsychopharmacol., 18, 10.1093/ijnp/pyv009 · DOI · Paper page
  4. Brauer, 1996, Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men., J. Clin. Psychopharmacol., 16, 72, 10.1097/00004714-199602000-00012 · DOI · Paper page
  5. Busto, 1986, Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective., Clin. Pharmacokinet., 11, 144, 10.2165/00003088-198611020-00004 · DOI
  6. Clausen, 2005, Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults., CNS Spectr., 10, 6, 10.1017/S109285290000239X · DOI · Paper page
  7. 2016, European Drug Report 2016.
  8. Farre, 1991, Pharmacokinetic considerations in abuse liability evaluation., Br. J. Addict., 86, 1601, 10.1111/j.1360-0443.1991.tb01754.x · DOI · Paper page
  9. Haffey, 2009, Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults., Postgrad. Med., 121, 11, 10.3810/pgm.2009.09.2048 · DOI · Paper page
  10. Heal, 2013, Amphetamine, past and present–a pharmacological and clinical perspective., J. Psychopharmacol., 27, 479, 10.1177/0269881113482532 · DOI · Paper page
  11. Hysek, 2012, Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex., Psychopharmacology, 224, 363, 10.1007/s00213-012-2761-6 · DOI
  12. Hysek, 2012, Duloxetine inhibits effects of MDMA (”ecstasy”) in vitro and in humans in a randomized placebo-controlled laboratory study., PLoS ONE, 7, 10.1371/journal.pone.0036476 · DOI · Paper page
  13. Hysek, 2014, Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination., Int. J. Neuropsychopharmacol., 17, 371, 10.1017/S1461145713001132 · DOI · Paper page
  14. Janke, 1978, Die Eigenschaftswörterliste.
  15. Johnston, 2016, Monitoring the Future: National Survey Results on Drug Use, 1975-2015: College Students and Adults Ages 19-55
  16. Kaland, 2015, Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers., Clin. Toxicol., 53, 477, 10.3109/15563650.2015.1027903 · DOI · Paper page
  17. Kirkpatrick, 2012, Acute and residual interactive effects of repeated administrations of oral methamphetamine and alcohol in humans., Psychopharmacology, 219, 191, 10.1007/s00213-011-2390-5 · DOI
  18. Krishnan, 2008, Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers., Clin. Drug Investig., 28, 745, 10.2165/0044011-200828120-00002 · DOI
  19. Lile, 2011, Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects., J. Clin. Pharmacol., 51, 888, 10.1177/0091270010375956 · DOI
  20. Parasrampuria, 2007, Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users., J. Clin. Psychopharmacol., 27, 459, 10.1097/jcp.0b013e3181515205 · DOI · Paper page
  21. Rosen, 1965, Absorption and excretion of radioactively tagged dextroamphetamine sulfate from a sustained-release preparation., JAMA, 194, 1203, 10.1001/jama.1965.03090240037010 · doi:10.1001/jama.1965.03090240037010
  22. Schmid, Acute effects of lysergic acid diethylamide in healthy subjects., Biol. Psychiatry, 78, 544, 10.1016/j.biopsych.2014.11.015 · DOI · Paper page
  23. Schmid, Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects., J. Pharmacol. Exp. Ther., 353, 102, 10.1124/jpet.114.222356 · DOI
  24. Simmler, 2013, Pharmacological characterization of designer cathinones in vitro., Br. J. Pharmacol., 168, 458, 10.1111/j.1476-5381.2012.02145.x · DOI · Paper page
  25. Simmler, 2014, Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives., Biochem. Pharmacol., 88, 237, 10.1016/j.bcp.2014.01.024 · DOI
  26. Smith, 2016, Individual differences in timing of peak positive subjective responses to d-amphetamine: relationship to pharmacokinetics and physiology., J. Psychopharmacol., 30, 330, 10.1177/0269881116631650 · DOI
  27. Zerssen, 1976, Die Beschwerden-Liste.

Cited by

See all 57

Metadata

Authors
Dolder, P. C., Strajhar, P., Vizeli, P., Hammann, F., Odermatt, A., & Liechti, M. E.
Venue
Frontiers in Pharmacology
Published
2017-09-07
Volume
8
Pages
617-617
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2750699103
Cited by
57
References
24
FWCI
4.98
Type
journal article
Language
en
Open access
gold
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_170249)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.